Korro Bio, Inc.KRRO

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$9.57
Market cap
$140.7M
P/E
—
Revenue (TTM)
$2.4M
Net income
-$106.6M
Dividend yield
—
1-year total return
-74.9%
Net margin
-4477.1%
Revenue growth
-62.1%
Debt / equity
—

What Korro Bio, Inc. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$37.0M$14.1M$0$0$2.3M$6.4M
Net income-$26.5M-$84.7M-$58.0M-$81.2M-$83.6M-$117.3M
Free cash flow-$51.9M-$79.0M-$58.8M-$75.1M-$78.0M-$79.1M

More on KRRO.

Figures from Korro Bio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.